Bipolar Disorder Therapeutics Market, By Drug Class (Mood Stabilizers, Anti Psychotics Drugs, and Antidepressant Drugs), By Mechanism of Action (Selective Serotonin Reuptake Inhibitors, Serotonin-Nor Epinephrine Reuptake Inhibitors, Tricyclic Antidepressants, Mono Amine Oxidase Inhibitors, Benzodiazepines, and Beta Blockers), and By Region - Global Opportunity Analysis and Industry Forecast, 2020 – 2030

Bipolar disorder is a mentally unstable condition that is prolonged for the lifetime and creates a series of manic, depression and mood swings. The patient dealing with such an issue leads to an unstable and unproductive life.  During the initial stage of manic, the person seems to be hyperactive and irresponsible, whereas, during the stage of depression, the person seems to be very calm and uninteractive. The bipolar disorder happens due to different reasons such as stress, self -esteem problems, childhood trauma, and another genetic inheritance issue. There are different stages for the same as the manic stage, hypomanic stage, and depressive stage. A large number of people in the world are suffering from mental illness which results in an increase in alcohol consumption among the people.  In order to spread awareness among the people around the world, 30th March is considered as World Bipolar Day. 

Market Segmentation:

Global bipolar disorder therapeutics market is segmented by type of drug class into mood stabilizers, antipsychotics drugs, and antidepressant drugs. By the mechanism of action, the market is categorized into selective serotonin reuptake inhibitors, serotonin-nor epinephrine reuptake inhibitors, tricyclic antidepressants, mono amine oxidase inhibitors, benzodiazepines, and beta-blockers. By geography, the bipolar disorder therapeutics market is segmented into North America, Asia Pacific, Europe, and the ROW. 

Market Dynamics and Factors:

Owing to the increase of bipolar disorder cases, medical needs, technological advancement, and world government initiatives to deal with more cases are the major factors which are driving the market. However, due to the lack of proper diagnostic procedures and proper identification of disorder and its side effects are the major restraints. Moving ahead the advancement in therapies of drugs and other social programs will help in the growth of the bipolar disorder therapeutics market. Social stigma related to this disease and unawareness among the people as to how to deal with the disorder related issue is the major challenges in the society.

Geographic Analysis:

North America dominates the global bipolar disorder therapeutics market due to an increase in awareness among the people, advancement in technology, advancement in healthcare sectors, the introduction of biosimilars and a rise in the prevalence of bipolar disorder. A large part of the population in the USA itself is undergoing the treatment for bipolar disorder and the count id nearly 48% of the total population. Europe is considered as the second-largest market for bipolar disorder therapeutics. Alos, the market for bipolar disorder therapeutics in the Asia Pacific is expected to expand at a higher growth rate due to an increase in investment in R&D, increasing awareness among people, increasing investment by pharmaceutical companies, and availability of skilled manpower for product manufacturing.

Competitive Scenario:

The key players operating in the global bipolar disorder therapeutics market include AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, Astellas Pharma Inc., Allergan plc. , Johnson & Johnson, GlaxoSmith Kline plc. AbbVie Inc., Pfizer Inc., and Novartis AG.

Bipolar Disorder Therapeutics Market Report Scope